TORONTO, July 14, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company“), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order…

Source

Previous articleMaximizing Mushrooms: How to Make a Little Psilocybin Go a Long Way
Next articleAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement